Araris Biotech AG to Present at Informa Connect's Next Generation Protein Therapeutics Summit
ZURICH, Switzerland, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the company’s chief executive officer, Philipp Spycher, Ph.D., will be a speaker at the Next Generation Protein Therapeutics Summit hosted by Informa Connect.
The presentation will highlight Araris’ proprietary linker technology, which enables the conjugation of various potent drug payloads to native “off-the-shelf” antibodies in a single step without the need for further engineering. In addition, the presentation will discuss how the resulting antibody-drug conjugates (ADCs) Araris is able to develop show favorable biophysical properties and demonstrate potent activity at very low doses in multiple in-vivo head-to-head studies with a significant improvement in therapeutic index. Further details about the presentation are provided below.
To register for the event, please visit Informa Connect’s website.
About Araris Biotech AG
Understanding Both Sides of the M&A Paradigm
Solutions Showcase Session
Grand Opening Reception in Expo Hall